Craig is Director Alliance Management and Sourcing, with responsibility for Central Labs, Imaging, Phase 1 and Early Access Programs.
Craig has worked for over 35 years in Clinical Research in both large pharma and small, medium and large CROs and academia performing a number of roles: CRA, line management, quality and training, alliance management, process improvement and strategic improvements. Craig has worked across multiple therapeutic areas and supported business development and operations interacting with large pharmaceutical companies and biotech sponsors. He has worked on a number of global strategic initiatives.
Craig is a PhD in Respiratory and Exercise Physiology and a BSc in Physiology and Biology. He is also a qualified cricket coach.
After receiving his scientific trainings in the areas of infectious diseases, oncology, and pharmacology at Institut Pasteur Paris, VU Amsterdam and DUKE-NUS Singapore, Ken started to advise on the R&D (e.g. academic/industry collab., clinical trials, manufacturing, RAs etc), intellectual properties, and investment (buy/sell) partnerships for 100+ small/listed biopharm companies worldwide. These were all thanks to his 10+ years of experience in Brinc, Hong Kong Science Park, an University tech transfer office, and an international patent agency. Currently, Ken is the Health Tech Counsel for the London office of the Government of Flanders. His role is to identify and advise on any biopharm / heath tech-focused collaborations between the ecosystem stakeholders in the UK, Ireland, and the Flanders region of Belgium.
Alecia Barry, PhD, joined Gilead in 2022 as Clinical Operations Franchise Head for Breast, Gynaecological and Genito-urinary Cancers. In her current role, Alecia oversees and leads a large group of oncology Clinical Operations professionals with global scope and accountability for operational strategy definition and trial execution to meet cost, speed and quality standards. Alecia serves a thought partner to the Oncology Clinical Development Franchise Heads providing strategic operational leadership and expertise. She is a member of the Clinical Operations Oncology Leadership Team with responsibilities for developing and evolving short- and long-range Clinical Operations strategies, plans, processes, tools and infrastructure development. Alecia functions as a Clinical Operations Vendor Lead for strategic CRO partnerships, with accountability to develop relationships, identify cross-portfolio issues, elevate to governance committees, and lead effective multi-level engagement and communication with Gilead and with CRO partners.
Alecia obtained her pharmacy degree, higher diploma in Quality Management and a PhD in Pharmaceutics from Trinity College, University of Dublin. Alecia has more than 15 years’ experience in the pharmaceutical industry across at various levels and positions in pharmaceutical development and clinical operations.
Farrell Healion is currently Senior Director Emerging Technologies, Global Clinical Solutions at AstraZeneca, where he leads the operational readiness delivery to scale up new technologies to be used in their clinical trials. He previously led their Digital Patient Solutions team that deliver patient-facing Digital Health Technologies(DHTs) such as eCOA across the AstraZeneca portfolio.
Starting out as an eCOA Developer at CRF Health, Farrell then moved through various technical leadership roles eventually leading the Technical and Project Management Office in Signant Health before moving to AstraZeneca. He is passionate about scaling up the use of patient and site-centric new DHTs in Clinical Trials, getting involved with various industry work groups such as DTRA and the eCOA Consortium. He is also the 2023 winner in Pharmatimes International Clinical Researcher of the Year award in the Decentralised Solutions category.
Lucy Moore has over twenty years of pharma industry experience, starting first as a Clinical Data Manager at Amgen where she took on roles of increasing responsibility as well as leading multiple continuous improvement projects. She joined AstraZeneca as a Data Management Expert in 2015 then quickly moved into more operations focused roles, leading the setup of a key Clinical Trial Delivery model across Data Management and Statistics/Statistical Programming before gaining additional operational experience in supporting a large clinical data focused department in Business Planning and Operations. In January 2021 she was asked to be the overall Business Programme Lead for the transformational Redefining Clinical Data Flow Programme, which is delivering streamlined data flow and improved system benefits to the company.
